| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 41.2 | 21.2 |
| Profit before tax | -55.6 | -78.6 |
| Net income | -55.1 | -79.1 |
| EPS (diluted, $ a share) | $-0.21 | $-0.30 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +94.6% |
|---|---|
| Operating margin | -105.6% |
10-Q filed with the SEC, NASDAQ: AUTL. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Autolus Therapeutics plc: key numbers
- Share price
- $1.14Close, Nov 16
- Market cap
- $304M
- Shares outstanding
- 266.34MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Autolus Therapeutics plc
All →Autolus Therapeutics Financial Results
Autolus Therapeutics reported Q3 2026 financial results, highlighted by $41.2 million in AUCATZYL net product revenue, a 95% year-over-year increase. The company raised its full-year 2026 revenue guidance for AUCATZYL to meet or exceed $150 million, driven by increased demand and manufacturing efficiencies that improved gross margins to 57%.
“We delivered another strong quarter of AUCATZYL revenue, primarily driven by growth within existing authorized treatment centers as physicians gain positive experience with the therapy, and supported by real-world data reported through the ROCCA consortium.”
Dr. Christian Itin, Chief Executive Officer
“AUCATZYL’s performance in adult r/r B-ALL is a key near-term value driver. Longer term, we believe expanding obe-cel across all stages of ALL and into autoimmune indications offers meaningful opportunities for scalable growth, leveraging its favorable profile and Autolus’ proven manufacturing and commercial capabilities.”
Dr. Christian Itin, Chief Executive Officer